Premium
Long‐term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real‐life experience from a tertiary referral center
Author(s) -
Dragoni Gabriele,
Bagnoli Siro,
Le Grazie Marco,
Campani Claudia,
Rogai Francesca,
Manetti Natalia,
Bensi Carolina,
Macrì Giuseppe,
Galli Andrea,
Milla Monica
Publication year - 2019
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12748
Subject(s) - medicine , vedolizumab , discontinuation , ulcerative colitis , inflammatory bowel disease , adverse effect , cohort , infliximab , gastroenterology , retrospective cohort study , surgery , tumor necrosis factor alpha , disease
Objective The study aimed to evaluate the long‐term efficacy and safety of vedolizumab in a real‐life cohort of patients with inflammatory bowel diseases enrolled at a tertiary referral center. Methods Data were retrospectively collected from August 2016 to November 2018. The primary outcomes were clinical response and remission at 14, 24, and 52 weeks, and steroid‐free remission rate (SFRR) at 52 weeks. Endoscopic response and remission rates at 52 weeks were the secondary outcomes. Results Altogether 49 patients (22 with ulcerating colitis [UC] and 27 with Crohn’s Disease [CD]) were enrolled. The clinical response rate gradually dropped from 85% and 50% in CD and UC, respectively, at week 14 to 59% and 25% at week 52, with significantly a higher response in CD at week 14. The endoscopic response at week 52 was 55% in CD and 25% in UC ( P = 0.21). CD group had a higher SFRR than UC group (41% vs 20%) at 52 weeks, although the difference was not statistically significant. Similar clinical and endoscopic rates were observed in biologic‐naive and ‐experienced patients. We reported no discontinuation due to adverse drug reactions, and only mild to moderate events. Conclusions In our cohort the clinical response in the induction phase was similar to those of registered trials, despite surprising better results for CD. During the maintenance phase we observed an higher drop out than in the reported literatures. Of note, its good safety profile makes vedolizumab a reliable choice in patients with contraindications to anti‐tumor necrosis factor agents.